Literature DB >> 8943274

The length of amyloid-beta in hereditary cerebral hemorrhage with amyloidosis, Dutch type. Implications for the role of amyloid-beta 1-42 in Alzheimer's disease.

E M Castaño1, F Prelli, C Soto, R Beavis, E Matsubara, M Shoji, B Frangione.   

Abstract

In hereditary cerebral hemorrhage with amyloidosis, Dutch type (HCHWA-D), a genetic variant (E22Q) of amyloid beta (Abeta) accumulates predominantly in the small vessels of leptomeninges and cerebral cortex, leading to fatal strokes in the fifth or sixth decade of life. Abeta deposition in the neuropil occurs mainly in the form of preamyloid, Congo red negative deposits, while mature neuritic plaques and neurofibrillary tangles, hallmark lesions in Alzheimer's disease (AD), are characteristically absent. A recent hypothesis regarding the pathogenesis of AD states that Abeta extending to residues 42-43 (as opposed to shorter species) can seed amyloid formation and trigger the development of neuritic plaques followed by neuronal damage in AD. We characterized biochemically and immunohistochemically Abeta from three cases of HCHWA-D to determine its length in vascular and parenchymal deposits. Mass spectrometry of formic acid-soluble amyloid, purified by size-exclusion gel chromatography, showed that Abeta 1-40 and its carboxyl-terminal truncated derivatives were the predominant forms in leptomeningeal and cortical vessels. Abeta 1-42 was a minor component in these amyloid extracts. Immunohistochemistry with antibodies S40 and S42, specific for Abeta ending at Val-40 or Ala-42, respectively, were consistent with the biochemical data from vascular amyloid. In addition, parenchymal preamyloid lesions were specifically stained with S42 and were not labeled by S40, in agreement with the pattern reported for AD, Down's syndrome, and aged dogs. Our results suggest that in HCHWA-D the carboxyl-terminal Abeta heterogeneity is due to limited proteolysis in vivo. Moreover, they suggest that Abeta species ending at Ala-42 may not be critical for the seeding of amyloid formation and the development of AD-like neuritic changes.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8943274     DOI: 10.1074/jbc.271.50.32185

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  23 in total

1.  Presenilin-1 is associated with Alzheimer's disease amyloid.

Authors:  T Wisniewski; W K Dowjat; B Permanne; J Palha; A Kumar; G Gallo; B Frangione
Journal:  Am J Pathol       Date:  1997-08       Impact factor: 4.307

2.  CEREBRAL AMYLOID ANGIOPATHY AND ALZHEIMER'S DISEASE.

Authors:  Jorge Ghiso; Yasushi Tomidokoro; Tamas Revesz; Blas Frangione; Agueda Rostagno
Journal:  Hirosaki Igaku       Date:  2010-07-08

3.  Amyloid imaging of dutch-type hereditary cerebral amyloid angiopathy carriers.

Authors:  Aaron P Schultz; Reina W Kloet; Hamid R Sohrabi; Louise van der Weerd; Sanneke van Rooden; Marieke J H Wermer; Laure Grand Moursel; Maqsood Yaqub; Bart N M van Berckel; Pratishtha Chatterjee; Samantha L Gardener; Kevin Taddei; Anne M Fagan; Tammie L Benzinger; John C Morris; Reisa Sperling; Keith Johnson; Randall J Bateman; M Edip Gurol; Mark A van Buchem; Ralph Martins; Jasmeer P Chhatwal; Steven M Greenberg
Journal:  Ann Neurol       Date:  2019-08-12       Impact factor: 10.422

4.  Tg-SwDI transgenic mice exhibit novel alterations in AbetaPP processing, Abeta degradation, and resilient amyloid angiopathy.

Authors:  Gregory D Van Vickle; Chera L Esh; Ian D Daugs; Tyler A Kokjohn; Walter M Kalback; R Lyle Patton; Dean C Luehrs; Douglas G Walker; Lih-Fen Lue; Thomas G Beach; Judianne Davis; William E Van Nostrand; Eduardo M Castaño; Alex E Roher
Journal:  Am J Pathol       Date:  2008-07-03       Impact factor: 4.307

Review 5.  Detection of actin cleavage in Alzheimer's disease.

Authors:  A LeBlanc
Journal:  Am J Pathol       Date:  1998-02       Impact factor: 4.307

6.  Matrix metalloproteinase 2 (MMP-2) degrades soluble vasculotropic amyloid-beta E22Q and L34V mutants, delaying their toxicity for human brain microvascular endothelial cells.

Authors:  Mar Hernandez-Guillamon; Stephanie Mawhirt; Silvia Fossati; Steven Blais; Mireia Pares; Anna Penalba; Merce Boada; Pierre-Olivier Couraud; Thomas A Neubert; Joan Montaner; Jorge Ghiso; Agueda Rostagno
Journal:  J Biol Chem       Date:  2010-06-24       Impact factor: 5.157

7.  Major involvement of low-density lipoprotein receptor-related protein 1 in the clearance of plasma free amyloid beta-peptide by the liver.

Authors:  Chihiro Tamaki; Sumio Ohtsuki; Takeshi Iwatsubo; Tadafumi Hashimoto; Kaoru Yamada; Chiori Yabuki; Tetsuya Terasaki
Journal:  Pharm Res       Date:  2006-06-21       Impact factor: 4.200

8.  Human blood-brain barrier receptors for Alzheimer's amyloid-beta 1- 40. Asymmetrical binding, endocytosis, and transcytosis at the apical side of brain microvascular endothelial cell monolayer.

Authors:  J B Mackic; M Stins; J G McComb; M Calero; J Ghiso; K S Kim; S D Yan; D Stern; A M Schmidt; B Frangione; B V Zlokovic
Journal:  J Clin Invest       Date:  1998-08-15       Impact factor: 14.808

9.  Tauroursodeoxycholic acid prevents E22Q Alzheimer's Abeta toxicity in human cerebral endothelial cells.

Authors:  R J S Viana; A F Nunes; R E Castro; R M Ramalho; J Meyerson; S Fossati; J Ghiso; A Rostagno; C M P Rodrigues
Journal:  Cell Mol Life Sci       Date:  2009-03       Impact factor: 9.261

Review 10.  Cerebral amyloidosis: amyloid subunits, mutants and phenotypes.

Authors:  A Rostagno; J L Holton; T Lashley; T Revesz; Jorge Ghiso
Journal:  Cell Mol Life Sci       Date:  2009-11-07       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.